On April 9, 2026 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, reported that the Company’s management will participate in the following investor conference:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Van Lanschot Kempen Life Sciences Conference
Date: April 16, 2026
Location: Amsterdam, The Netherlands
Attendee: Julia Neugebauer, PhD, COO

(Press release, Vivoryon Therapeutics, APR 9, 2026, View Source [SID1234664273])